Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by TD Asset Management Inc

TD Asset Management Inc lifted its position in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) by 92.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 40,800 shares of the biopharmaceutical company’s stock after buying an additional 19,600 shares during the quarter. TD Asset Management Inc owned approximately 0.38% of Corbus Pharmaceuticals worth $1,846,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of CRBP. Ikarian Capital LLC raised its holdings in shares of Corbus Pharmaceuticals by 185.5% in the 1st quarter. Ikarian Capital LLC now owns 559,271 shares of the biopharmaceutical company’s stock valued at $21,946,000 after buying an additional 363,372 shares during the period. Janus Henderson Group PLC purchased a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at $13,363,000. Vanguard Group Inc. raised its holdings in shares of Corbus Pharmaceuticals by 143.7% in the 1st quarter. Vanguard Group Inc. now owns 437,264 shares of the biopharmaceutical company’s stock valued at $17,158,000 after buying an additional 257,808 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at $7,554,000. Finally, Altitude Crest Partners Inc. purchased a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at $4,069,000. Hedge funds and other institutional investors own 64.64% of the company’s stock.

Analyst Upgrades and Downgrades

CRBP has been the topic of several research analyst reports. Lifesci Capital upgraded Corbus Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, August 21st. Oppenheimer upped their price target on Corbus Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a report on Wednesday, August 7th. StockNews.com downgraded Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 10th. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Corbus Pharmaceuticals in a report on Tuesday, August 6th. Finally, B. Riley assumed coverage on Corbus Pharmaceuticals in a report on Wednesday, June 26th. They set a “buy” rating and a $85.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.67.

Insiders Place Their Bets

In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 11,103 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $46.02, for a total transaction of $510,960.06. Following the completion of the sale, the chief executive officer now directly owns 84,400 shares of the company’s stock, valued at approximately $3,884,088. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Corbus Pharmaceuticals news, CEO Yuval Cohen sold 11,103 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $46.02, for a total transaction of $510,960.06. Following the completion of the sale, the chief executive officer now directly owns 84,400 shares of the company’s stock, valued at approximately $3,884,088. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sean F. Moran sold 1,958 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $42.12, for a total value of $82,470.96. Following the sale, the chief financial officer now directly owns 48,605 shares of the company’s stock, valued at $2,047,242.60. The disclosure for this sale can be found here. 4.00% of the stock is owned by insiders.

Corbus Pharmaceuticals Stock Performance

NASDAQ:CRBP opened at $55.81 on Friday. The stock has a 50-day simple moving average of $55.84 and a 200-day simple moving average of $46.45. The stock has a market cap of $671.95 million, a P/E ratio of -8.02 and a beta of 2.56. Corbus Pharmaceuticals Holdings, Inc. has a 1 year low of $3.03 and a 1 year high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.19) by $0.29. On average, equities research analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post -3.77 EPS for the current year.

Corbus Pharmaceuticals Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.